Information Library

Reducing Complexity

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • New York State's New PACeR Clinical Data Network

    August 5, 2010
    This briefing describes how the PACeR initiative has connected hospitals, physicians, patients' homes and pharmaceutical scientists to provide valuable insights into current, real-world medical practices.

  • Podcast: Clinical Data Standards

    May 11, 2010
    Paula Brown Stafford, Executive Vice President of Integrated Clinical Services, Quintiles, and Chair-elect of CDISC, the Clinical Data Interchange Standards Consortium, explains the importance of data standards in clinical trial execution and how improvements in data collection can better ensure patient safety.

  • Shaping Clinical Transformation

    November 18, 2009
    A summary of key insights exchanged between pharma executives at the inaugural Quintiles Consulting Executive Vision Forum.

  • Podcast: Changing the Face of Cancer Research

    August 31, 2009
    Christopher Ung, Vice President, Strategic Business & Operations, Oncology, Quintiles, explains how advances in biomarker technology are ushering in a new era of cancer therapy development.

  • The New Face of Clinical Data Management

    March 31, 2009
    Discusses the new face of clinical data management in today's biopharmaceutical industry.

  • Reinventing the Clinical Trial

    March 31, 2009
    As a new era of drug discovery unfolds, reinventing the clinical trial is essential to medical advancement.

  • Advancing Drug Development Through Pharmacogenomics

    March 31, 2009
    Pharmacogenomics (PG x) is the study of how such genetic differences influence drug therapy. The goal is to use a person’s DNA profile to predict how the individual will respond to a medicine. The ability to predict drug response holds enormous promise to advance the drug development process and to improve drug safety and effectiveness in medical practice.

  • Overcoming Global Challenges

    March 2, 2009
    Learn about strategies to overcome globalization challenges from John Doyle, Market Access Practice Leader, and Geoff Garabedian, Regulatory and Quality Systems Practice Leader in podcast brought to you by PharmaVoice.

Page 1 of 1 (8 results)

Subscribe to Email Based on Your Interests

Set preferences